Home › Funds › Venrock Adviser, LLC › MAZE
Venrock Adviser, LLC position in MAZE
MAZE THERAPEUTICS INC · Health Care
Venrock Adviser, LLC reported holding 1,602,034 shares of MAZE (MAZE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$47.8M, representing 1.45% of its reported portfolio and ranking #14 among its reported holdings. Venrock Adviser, LLC has disclosed MAZE holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Venrock Adviser, LLC's MAZE position evolved
Venrock Adviser, LLC first disclosed a stake in MAZE in Q3 2025 at 1,230,769 shares (US$31.9M). The position peaked in Q4 2025 at 1,548,569 shares, worth US$64.2M. Across 4 filings, Venrock Adviser, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,602,034 shares valued at US$47.8M. Notable position changes include a 26% increase in Q4 2025 (shares fell 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 1.23M | $31.91M | New |
| Q4 2025 | 1.55M | $64.16M | Add |
| Q1 2026 | 1.60M | $47.82M | Add |
| Q2 2026 | 1.60M | $47.80M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MAZE and 13F data
MAZE (MAZE THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in MAZE — the largest reported positions include Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MAZE
- Frazier Life Sciences Management, L.P. 5.03M sh · $150.18M · Q2 2026
- TRV GP IV, LLC 4.47M sh · $133.50M · Q2 2026
- ARCH Venture Management, LLC 4.12M sh · $122.98M · Q2 2026
- Deep Track Capital, LP 3.73M sh · $111.38M · Q2 2026
- Logos Global Management LP 1.94M sh · $57.74M · Q2 2026
- a16z Capital Management, L.L.C. 1.70M sh · $50.79M · Q2 2026
- Alphabet Inc. 1.39M sh · $41.44M · Q2 2026
- BRAIDWELL LP 1.14M sh · $34.02M · Q2 2026
- Farallon Capital Management 1.11M sh · $33.06M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.11M sh · $33.06M · Q2 2026
- General Catalyst Group Management, LLC 1.04M sh · $30.91M · Q2 2026
- TRV GP V, LLC 950.80K sh · $28.37M · Q2 2026
More on Venrock Adviser, LLC
FAQ
How long has Venrock Adviser, LLC held MAZE?
Venrock Adviser, LLC has disclosed MAZE holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Venrock Adviser, LLC's current position in MAZE?
As of Q2 2026, Venrock Adviser, LLC holds 1.60M shares of MAZE (MAZE THERAPEUTICS INC), valued at $47.80M, representing 1.45% of its reported portfolio and ranking #14.
Has Venrock Adviser, LLC been buying or selling MAZE?
In the latest 13F filing (Q2 2026), Venrock Adviser, LLC held unchanged its position in MAZE. The position peaked in Q4 2025 at 1.55M shares.
Which other funds hold MAZE?
Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.